In addition, the combination of anti-CD40 and anti-CSF-1R not only promotes the maturation and differentiation of inflammatory macrophages and DCs but also drives the effective initiation of effector T cells during cancer immunotherapy [108]. This evidence concerns the gene CSF1R and cancer.